08:32 AM EDT, 09/02/2025 (MT Newswires) -- CorMedix ( CRMD ) said Tuesday it has completed the purchase of Melinta Therapeutics.

The company paid $300 million in upfront payment, comprised of $260 million in cash and $40 million in Cormediz equity issued to Deerfield Management.

The agreement also consists additional regulatory milestone payment of up to $25 million for the FDA approval of the expanded indication of Rezzayo for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if the milestone event is achieved by June 30, 2029.

Aside from the regulatory milestone payment, the consideration also includes tiered royalties on net sales of Minocin and Rezzayo.

The acquisition is expected to be "highly accretive" in 2026 and deliver $125 million to $135 million of revenue for full-year 2025, CorMedix ( CRMD ) said.

The company said it revised its full-year 2025 revenue guidance to now be between $325 million and $350 million from the prior range of between $305 million and $335 million.

Melinta CFO Susan Blum will assume the same role in the newly merged company, while CorMedix CFO Matt David will take the role of chief business officer. Meanwhile, CorMedix ( CRMD ) Chief Clinical Strategy and Operations Officer Liz Hurlburt will become COO and chief integration officer.